Scorpius BioManufacturing, a Texas-based biologics contract research and contract development & manufacturing organization, announced the appointment of Gary Welch as Interim President.
Scorpius BioManufacturing Announces the Appointment of Gary Welch as Interim President Read More »
Oxford Nanopore Technologies plc and PathoQuest announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.
Mainz Biomed NV announced that Bill Caragol, the Company’s CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 22-23, 2023.
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23 Read More »
The European Commission has approved Dupixent® in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.
Nicox SA, an international ophthalmology company, announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress which will be held from June 28 to July 1st, 2023 in Rome, Italy.
The Centers for Medicare & Medicaid Services has awarded Dynanet a Prime contract to provide services under the Agile Collaboration and Modernization Endeavors Blanket Purchase Agreement.
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.
Prestige Biopharma has received Fast Track designation from the U.S. Food and Drug Administration for PBP1510, in the treatment of unresectable or metastatic pancreatic adenocarcinoma that has relapsed following and/or is refractory to at least one line of prior therapy.
On Feb. 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024. BioSpace takes a deep dive into the vaccine maker’s prospects.
Características clínicas y opciones terapéuticas de las repercusiones orgánicas por la exposición laboral al carbón, sílice y amianto
Enfermedades ocupacionales respiratorias | Neumoconiosis Read More »
